ProCE Banner Activity

HPTN 083: Long-Acting Injectable CAB Superior to Daily Oral TDF/FTC as PrEP in MSM and TGW at High Risk of HIV Infection

Slideset Download
Conference Coverage
Long-acting CAB injected intramuscularly every 2 months reduced the risk of HIV infection by 66% compared with daily oral TDF/FTC in high-risk MSM and transgender women.

Released: July 11, 2020

Expiration: July 10, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by:

Gilead

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

AIDS 2020

ProCE Banner

IAS 2018

ProCE Banner